PDUFA Date is June 21, 2023
Planned U.S. Launch of ADX-2191 in Second Half of 2023, Pending Approval by the FDA
ADX-2191 with Potential to be the First FDA-Approved Drug Available for Patients Suffering from Primary Vitreoretinal Lymphoma
https://finance.yahoo.com/news/fda-accepts-priority-review-adx-120000024.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.